Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


The role of misclassification of exposure in the association between aspirin and nonsteroidal anti-inflammatory drug use and keratinocyte cancers.

Abtahi S, Oshagbemi OA, van Veelen A, van Geel RMJM.

Br J Dermatol. 2019 Sep;181(3):642. doi: 10.1111/bjd.18134. Epub 2019 Jul 1. No abstract available.


A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM.

Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.


Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA, Freshwater T, Beijnen JH, Schellens JH.

J Clin Oncol. 2016 Dec 20;34(36):4354-4361. Epub 2016 Oct 28.


Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, Lam R, Demuth T, Rose S, Lee MA, Freshwater T, Shumway S, Liang LW, Oza AM, Schellens JH, Shapiro GI.

J Clin Oncol. 2016 Dec 20;34(36):4371-4380. doi: 10.1200/JCO.2016.67.5991. Epub 2016 Oct 31.


Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F.

Cancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16.


Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH.

Br J Clin Pharmacol. 2016 Sep;82(3):706-16. doi: 10.1111/bcp.13007. Epub 2016 Jun 3.


Crizotinib-induced fatal fulminant liver failure.

van Geel RM, Hendrikx JJ, Vahl JE, van Leerdam ME, van den Broek D, Huitema AD, Beijnen JH, Schellens JH, Burgers SA.

Lung Cancer. 2016 Mar;93:17-9. doi: 10.1016/j.lungcan.2015.12.010. Epub 2015 Dec 30.


Treatment Individualization in Colorectal Cancer.

van Geel RM, Beijnen JH, Bernards R, Schellens JH.

Curr Colorectal Cancer Rep. 2015;11(6):335-344. Epub 2015 Aug 26. Review.


Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

Pluim D, Jacobs BA, Deenen MJ, Ruijter AE, van Geel RM, Burylo AM, Meulendijks D, Beijnen JH, Schellens JH.

Bioanalysis. 2015;7(5):519-29. doi: 10.4155/bio.14.304.


Concise drug review: pazopanib and axitinib.

van Geel RM, Beijnen JH, Schellens JH.

Oncologist. 2012;17(8):1081-9. doi: 10.1634/theoncologist.2012-0055. Epub 2012 Jun 25. Review.

Supplemental Content

Loading ...
Support Center